Niraparib
Treatment for Ovarian Cancer
Typical Dosage: 200-300 mg once daily
Effectiveness
77%
Safety Score
50%
Clinical Trials
95
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
200-300 mg once daily
Time to Effect
1-3 months
Treatment Duration
2-3 years
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3(Treat 3 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$192,000
Monitoring:$7,000
Side Effect Mgmt:$4,000
Total Annual:$203,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$130,000/QALY
QALYs Gained
2.6
Outcome-Based Costs
Cost per Responder
$298,529
Cost per Remission
$812,000
Comparison vs Carboplatin + Paclitaxel (chemotherapy alone)
Cost Difference
+$183,000/year
More expensive
QALY Difference
+0.60 QALYs
Better outcomes
Dominance
No dominance
Niraparib Outcomes
for Ovarian Cancer
Efficacy Outcomes
Overall Effectiveness
+77%
Response Rate
+68%
Remission Rate
+25%
Common Side Effects
Thrombocytopenia
+35%
Anemia
+25%
Nausea
+55%
Fatigue
+45%
Hypertension
+25%
Sources:
Active Clinical Trials
8 active trials recruiting for Niraparib in Ovarian Cancer
A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
NCT06887933NOT YET RECRUITINGPHASE4
67 participants
INTERVENTIONAL
Started: Apr 22, 2025
Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency
NCT06827353RECRUITING
300 participants
OBSERVATIONAL
Nîmes, France
Started: Oct 1, 2020
Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer
NCT07059676NOT YET RECRUITING
120 participants
OBSERVATIONAL
Started: Jul 25, 2025
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
NCT04641247RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Tucson, United States +24 more
Started: Apr 16, 2021
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016ACTIVE NOT RECRUITINGPHASE3
733 participants
INTERVENTIONAL
Tempe, United States +199 more
Started: Jul 11, 2016
Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
NCT04507841ACTIVE NOT RECRUITINGPHASE2
67 participants
INTERVENTIONAL
Wuhan, China
Started: Jan 8, 2021
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
NCT06412120RECRUITINGPHASE4
70 participants
INTERVENTIONAL
Fort Lauderdale, United States +1 more
Started: Mar 1, 2026
A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice
NCT05021562ACTIVE NOT RECRUITING
354 participants
OBSERVATIONAL
Tokyo, Japan
Started: Sep 13, 2021
Completed Clinical Trials
8 completed trials for Niraparib in Ovarian Cancer
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
NCT05751629COMPLETEDPHASE2
41 participants
INTERVENTIONAL
Birmingham, United States +9 more
Started: Nov 15, 2018
Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study
NCT05734911COMPLETED
199 participants
OBSERVATIONAL
Nanjing, China
Started: Jan 1, 2019
The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer
NCT06086665COMPLETED
850 participants
OBSERVATIONAL
Seoul, South Korea
Started: Dec 1, 2019
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT03326193COMPLETEDPHASE2
105 participants
INTERVENTIONAL
Mobile, United States +28 more
Started: Dec 12, 2017
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
NCT02354586COMPLETEDPHASE2
463 participants
INTERVENTIONAL
Chandler, United States +54 more
Started: Mar 23, 2015
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
NCT01847274COMPLETEDPHASE3
596 participants
INTERVENTIONAL
Phoenix, United States +111 more
Started: Jun 21, 2013
Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting
NCT04284852COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Hong Kong, Hong Kong
Started: May 1, 2020
NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.
NCT03752216COMPLETEDPHASE4
141 participants
INTERVENTIONAL
Avignon, France +29 more
Started: Apr 3, 2019
Showing 20 of 95 total trials